Ibero-American Expert Consensus on Squamous Cell Carcinoma of the Head and Neck Treatment in Patients Unable to Receive Cisplatin: Recommendations for Clinical Practice

References

• AdelsteinDJ, LiY, AdamsGL, et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003;21(1):92–98. doi:10.1200/JCO.2003.01.00812506176
   PubMed Web of Science ®Google Scholar
• ForastiereAA, ZhangQ, WeberRS, et al. Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol. 2013;31(7):845–852. doi:10.1200/JCO.2012.43.609723182993
   PubMed Web of Science ®Google Scholar
• GillisonML, TrottiAM, HarrisJ, et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet. 2019;393(10166):40–50. doi:10.1016/S0140-6736(18)32779-X30449625
   PubMed Web of Science ®Google Scholar
• VermorkenJB, MesíaR, RiveraF, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med. 2008;359(11):1116–1127. doi:10.1056/NEJMoa080265618784101
   PubMed Web of Science ®Google Scholar
• BurtnessB, HarringtonKJ, GreilR, et al. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, Phase 3 study. Lancet. 2019;394(10212):1915–1928. doi:10.1016/S0140-6736(19)32591-731679945
   PubMed Web of Science ®Google Scholar
• BernierJ, DomengeC, OzsahinM, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350(19):1945–1952. doi:10.1056/NEJMoa03264115128894
   PubMed Web of Science ®Google Scholar
• AhnMJ, D’CruzA, VermorkenJB, et al. Clinical recommendations for defining platinum unsuitable head and neck cancer patient populations on chemoradiotherapy: a literature review. Oral Oncol. 2016;53:10–16. doi:10.1016/j.oraloncology.2015.11.01926712252
   PubMed Web of Science ®Google Scholar
• de CastroGJr, AlvesGV, CastroAF, et al. Criteria for eligibility to cisplatin in the curative treatment of head and neck cancer: consensus opinion from a panel of experts. Crit Rev Oncol Hematol. 2018;131:30–34. doi:10.1016/j.critrevonc.2018.08.00930293703
   PubMed Web of Science ®Google Scholar
• PorcedduSV, ScotteF, AaproM, et al. Treating patients with locally advanced squamous cell carcinoma of the head and neck unsuitable to receive cisplatin-based therapy. Front Oncol. 2020;9:1522. doi:10.3389/fonc.2019.0152232039012
   PubMed Web of Science ®Google Scholar
• SyrigosKN, KarachaliosD, KarapanagiotouEM, NuttingCM, ManolopoulosL, HarringtonKJ. Head and neck cancer in the elderly: an overview on the treatment modalities. Cancer Treat Rev. 2009;35(3):237–245. doi:10.1016/j.ctrv.2008.11.00219100689
   PubMed Web of Science ®Google Scholar
• PorcedduSV, HaddadRI. Management of elderly patients with locoregionally confined head and neck cancer. Lancet Oncol. 2017;18(5):e274–e283. doi:10.1016/S1470-2045(17)30229-228456589
   PubMed Web of Science ®Google Scholar
• SzturzP, BossiP, VermorkenJB. Systemic treatment in elderly head and neck cancer patients: recommendations for clinical practice. Curr Opin Otolaryngol Head Neck Surg. 2019;27(2):142–150. doi:10.1097/MOO.000000000000052630694914
   PubMed Web of Science ®Google Scholar
• MaggioreR, ZumstegZS, BrintzenhofeSzocK, et al. The older adult with locoregionally advanced head and neck squamous cell carcinoma: knowledge gaps and future direction in assessment and treatment. Int J Radiat Oncol Biol Phys. 2017;98(4):868–883. doi:10.1016/j.ijrobp.2017.02.02228602414
   PubMed Web of Science ®Google Scholar
• AntonioM, HonoratoM, PlanaM, et al. 934P comparing frailty screening tools for older head and neck cancer patients. Ann Oncol. 2020;31(Suppl 4):S670. doi:10.1016/j.annonc.2020.08.1049
   Web of Science ®Google Scholar
• LacasB, CarmelA, LandaisC, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 107 randomized trials and 19805 patients, on behalf of MACH-NC group. Radiother Oncol. 2021;156:281–293. doi:10.1016/j.radonc.2021.01.01333515668
   PubMed Web of Science ®Google Scholar
• GuigayJ, AuperinA, MertensC, et al. Personalized treatment according to geriatric assessment in 1st line recurrent and/or metastatic (R/M) Head and Neck Squamous Cell Cancer (HNSCC) patients aged 70 or over. ELAN (ELderly heAd and Neck cancer) FIT and UNFIT trials. Ann Oncol. 2019;30(Suppl5):Abstract3250. doi:10.1093/annonc/mdz252.002
   Google Scholar
• ArgirisA, LiY, MurphyBA, LangerCJ, ForastiereAA. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol. 2004;22(2):262–268. doi:10.1200/JCO.2004.08.03914722034
   PubMed Web of Science ®Google Scholar
• WardMC, ReddyCA, AdelsteinDJ, KoyfmanSA. Use of systemic therapy with definitive radiotherapy for elderly patients with head and neck cancer: a national cancer data base analysis. Cancer. 2016;122(22):3472–3483. doi:10.1002/cncr.3021427504955
   PubMed Web of Science ®Google Scholar
• WoodyNM, WardMC, KoyfmanSA, et al. Adjuvant chemoradiation after surgical resection in elderly patients with high-risk squamous cell carcinoma of the head and neck: a national cancer database analysis. Int J Radiat Oncol Biol Phys. 2017;98(4):784–792. doi:10.1016/j.ijrobp.2017.03.01928602410
   PubMed Web of Science ®Google Scholar
• CooperJS, PajakTF, ForastiereAA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350(19):1937–1944. doi:10.1056/NEJMoa03264615128893
   PubMed Web of Science ®Google Scholar
• SaraswathulaA, ChenMM, ColevasAD, DiviV. Assessing care value for older patients receiving radiotherapy with or without cisplatin or cetuximab for locoregionally advanced head and neck cancer. JAMA Otolaryngol Head Neck Surg. 2019;145(12):1160–1167. doi:10.1001/jamaoto.2019.238131621810
   PubMed Web of Science ®Google Scholar
• Muller von der GrunJ, MartinD, StoverT, GhanaatiS, RodelC, BalermpasP. Chemoradiotherapy as definitive treatment for elderly patients with head and neck cancer. Biomed Res Int. 2018;2018:3508795. doi:10.1155/2018/350879529581971
   PubMed Web of Science ®Google Scholar
• MachtayM, MoughanJ, TrottiA, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol. 2008;26(21):3582–3589. doi:10.1200/JCO.2007.14.884118559875
   PubMed Web of Science ®Google Scholar
• CapuanoG, GrossoA, GentilePC, et al. Influence of weight loss on outcomes in patients with head and neck cancer undergoing concomitant chemoradiotherapy. Head Neck. 2008;30(4):503–508. doi:10.1002/hed.2073718098310
   PubMed Web of Science ®Google Scholar
• PawarD, AhmedR, ChaudhariS. A survey of on platinum ineligible in head and neck cancer patients in India. Ann Oncol. 2017;28(Suppl 10):Abstract520P. doi:10.1093/annonc/mdx676.019
   Google Scholar
• GhadjarP, HayozS, ZimmermannF, et al. Impact of weight loss on survival after chemoradiation for locally advanced head and neck cancer: secondary results of a randomized phase III trial (SAKK 10/94). Radiat Oncol. 2015;10(1):21. doi:10.1186/s13014-014-0319-y25679310
   PubMed Web of Science ®Google Scholar
• ArribasL, HurtósL, TabernaM, et al. Nutritional changes in patients with locally advanced head and neck cancer during treatment. Oral Oncol. 2017;71:67–74. doi:10.1016/j.oraloncology.2017.06.00328688694
   PubMed Web of Science ®Google Scholar
• TalwarB, DonnellyR, SkellyR, DonaldsonM. Nutritional management in head and neck cancer: United Kingdom national multidisciplinary guidelines. J Laryngol Otol. 2016;130(S2):S32–S40. doi:10.1017/S0022215116000402
   PubMed Web of Science ®Google Scholar
• LangerT, Am Zehnhoff-DinnesenA, RadtkeS, MeitertJ, ZolkO. Understanding platinum-induced ototoxicity. Trends Pharmacol Sci. 2013;34(8):458–469. doi:10.1016/j.tips.2013.05.00623769626
   PubMed Web of Science ®Google Scholar
• McWhinneySR, GoldbergRM, McLeodHL. Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009;8(1):10–16. doi:10.1158/1535-7163.MCT-08-084019139108
   PubMed Web of Science ®Google Scholar
• CharlsonME, PompeiP, AlesKL, MacKenzieCR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373–383. doi:10.1016/0021-9681(87)90171-83558716
   PubMedGoogle Scholar
• CharlsonME, CharlsonRE, PetersonJC, MarinopoulosSS, BriggsWM, HollenbergJP. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–1240. doi:10.1016/j.jclinepi.2008.01.00618619805
   PubMed Web of Science ®Google Scholar
• ShihCA, ChenWC, YuHC, et al. Risk of severe acute exacerbation of chronic HBV infection cancer patients who underwent chemotherapy and did not receive anti-viral prophylaxis. PLoS One. 2015;10(8):e0132426. doi:10.1371/journal.pone.013242626274393
   PubMed Web of Science ®Google Scholar
• LiuPP. Cardiorenal syndrome in heart failure: a cardiologist’s perspective. Can J Cardiol. 2008;24(SupplB):25B–29B. doi:10.1016/S0828-282X(08)71027-4
   PubMed Web of Science ®Google Scholar
• SzturzP, CristinaV, Herrera GómezRG, BourhisJ, SimonC, VermorkenJB. Cisplatin eligibility issues and alternative regimens in locoregionally advanced head and neck cancer: recommendations for clinical practice. Front Oncol. 2019;9:464. doi:10.3389/fonc.2019.0046431245288
   PubMed Web of Science ®Google Scholar
• RudekMA, FlexnerC, AmbinderRF. Use of antineoplastic agents in patients with cancer who have HIV/AIDS. Lancet Oncol. 2011;12(9):905–912. doi:10.1016/S1470-2045(11)70056-021570912
   PubMed Web of Science ®Google Scholar
• KawsarHI, ShahnewazJ, GopalakrishnaKV, SpiroTP, DawHA. Hepatitis B reactivation in cancer patients: role of prechemotherapy screening and antiviral prophylaxis. Clin Adv Hematol Oncol. 2012;10(6):370–378.22895238
   PubMedGoogle Scholar
• MahaleP, SturgisEM, TweardyDJ, Ariza-HerediaEJ, TorresHA. Association between hepatitis C virus and head and neck cancers. J Natl Cancer Inst. 2016;108(8):djw035. doi:10.1093/jnci/djw035
   PubMedGoogle Scholar
• RangelJB, ThulerLCS, PintoJ. Prevalence of hepatitis C virus infection and its impact on the prognosis of head and neck cancer patients. Oral Oncol. 2018;87:138–143. doi:10.1016/j.oraloncology.2018.10.02430527229
   PubMed Web of Science ®Google Scholar
• LeeLY, CazierJB, AngelisV, et al. COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort study. Lancet. 2020;395(10241):1919–1926. doi:10.1016/S0140-6736(20)31173-932473682
   PubMed Web of Science ®Google Scholar
• de FeliceF, PolimeniA, TomboliniV. The impact of coronavirus (COVID-19) on head and neck cancer patients’ care. Radiother Oncol. 2020;147:84–85. doi:10.1016/j.radonc.2020.03.02032247204
   PubMed Web of Science ®Google Scholar
• ChavesALF, CastroAF, MartaGN, et al. Emergency changes in international guidelines on treatment for head and neck cancer patients during the COVID-19 pandemic. Oral Oncol. 2020;107:104734. doi:10.1016/j.oraloncology.2020.10473432353793
   PubMed Web of Science ®Google Scholar
• Grupo Español del Tratamiento de Tumores de Cabeza y Cuello. Recomendaciones de tratamiento del cáncer de cabeza y cuello (pandemia SARS-CoV-2); 2020.
   Google Scholar
• GietemaJA, MeinardiMT, MesserschmidtJ, et al. Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer. Lancet. 2000;355(9209):1075–1076. doi:10.1016/S0140-6736(00)02044-410744098
   PubMed Web of Science ®Google Scholar
• StrojanP, VermorkenJB, BeitlerJJ, et al. Cumulative cisplatin dose in concurrent chemoradiotherapy for head and neck cancer: a systematic review. Head Neck. 2016;38(Suppl 1):E2151–2158. doi:10.1002/hed.2402625735803
   PubMed Web of Science ®Google Scholar
• MakriliaN, SyrigouE, KaklamanosI, ManolopoulosL, SaifMW. Hypersensitivity reactions associated with platinum antineoplastic agents: a systematic review. Met Based Drugs. 2010;2010:1–11. doi:10.1155/2010/207084
   Google Scholar
• National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. head and neck cancers. Version 1.2021; 119, 2020. Available from:https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 1116, 2020.
   Google Scholar
• MesiaR, IglesiasL, LambeaJ, et al. SEOM clinical guidelines for the treatment of head and neck cancer (2020). Clin Transl Oncol. 2021;23(5):913–921.33635468
   PubMed Web of Science ®Google Scholar
• DenisF, GaraudP, BardetE, et al. Final results of the 94-01 French head and neck oncology and radiotherapy group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22(1):69–76. doi:10.1200/JCO.2004.08.02114657228
   PubMed Web of Science ®Google Scholar
• HanemaaijerSH, KokIC, FehrmannRSN, et al. Comparison of carboplatin with 5-fluorouracil vs. cisplatin as concomitant chemoradiotherapy for locally advanced head and neck squamous cell carcinoma. Front Oncol. 2020;10:761. doi:10.3389/fonc.2020.0076132582534
   PubMed Web of Science ®Google Scholar
• GuanJ, LiQ, ZhangY, et al. A meta-analysis comparing cisplatin-based to carboplatin-based chemotherapy in moderate to advanced squamous cell carcinoma of head and neck (SCCHN). Oncotarget. 2016;7(6):7110–7119. doi:10.18632/oncotarget.685826755647
   PubMedGoogle Scholar
• BonnerJA, HarariPM, GiraltJ, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354(6):567–578. doi:10.1056/NEJMoa05342216467544
   PubMed Web of Science ®Google Scholar
• BonnerJA, HarariPM, GiraltJ, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol. 2010;11(1):21–28. doi:10.1016/S1470-2045(09)70311-019897418
   PubMed Web of Science ®Google Scholar
• LeeYG, KangEJ, KeamB, et al. Treatment strategy and outcomes in locally advanced head and neck squamous cell carcinoma: a nationwide retrospective cohort study (KCSG HN13-01). BMC Cancer. 2020;20(1):813. doi:10.1186/s12885-020-07297-z32854649
   PubMed Web of Science ®Google Scholar
• HittR, IrigoyenA, Cortes-FunesH, et al. Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck. Ann Oncol. 2012;23(4):1016–1022. doi:10.1093/annonc/mdr36721865152
   PubMed Web of Science ®Google Scholar
• BachaudJM, Cohen-JonathanE, AlzieuC, DavidJM, SerranoE, Daly-SchveitzerN. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced head and neck carcinoma: final report of a randomized trial. Int J Radiat Oncol Biol Phys. 1996;36(5):999–1004. doi:10.1016/S0360-3016(96)00430-08985019
   PubMed Web of Science ®Google Scholar
• NoronhaV, JoshiA, PatilVM, et al. Once-a-week versus once-every-3-weeks cisplatin chemoradiation for locally advanced head and neck cancer: a phase III randomized noninferiority trial. J Clin Oncol. 2018;36(11):1064–1072. doi:10.1200/JCO.2017.74.945729220295
   PubMed Web of Science ®Google Scholar
• KiyotaN, TaharaM, FujiiH, et al. Phase II/III trial of post-operative chemoradiotherapy comparing 3-weekly cisplatin with weekly cisplatin in high-risk patients with squamous cell carcinoma of head and neck (JCOG1008). J Clin Oncol. 2020;38(15 Suppl):Abstract 6502. doi:10.1200/JCO.2020.38.15_suppl.6502
   Web of Science ®Google Scholar
• TsanDL, LinCY, KangCJ, et al. The comparison between weekly and three-weekly cisplatin delivered concurrently with radiotherapy for patients with postoperative high-risk squamous cell carcinoma of the oral cavity. Radiat Oncol. 2012;7(1):215. doi:10.1186/1748-717X-7-21523245290
   PubMed Web of Science ®Google Scholar
• LacasB, BourhisJ, OvergaardJ, et al. Role of radiotherapy fractionation in head and neck cancers (MARCH): an updated meta-analysis. Lancet Oncol. 2017;18(9):1221–1237. doi:10.1016/S1470-2045(17)30458-828757375
   PubMed Web of Science ®Google Scholar
• SanabriaA, DomengeC, D’CruzA, KowalskiLP. Organ preservation protocols in developing countries. Curr Opin Otolaryngol Head Neck Surg. 2010;18(2):83–88. doi:10.1097/MOO.0b013e3283378f4020216217
   PubMed Web of Science ®Google Scholar
• IsakssonJ, WilmsT, LaurellG, FranssonP, EhrssonYT. Meaning of work and the process of returning after head and neck cancer. Support Care Cancer. 2016;24(1):205–213. doi:10.1007/s00520-015-2769-726003423
   PubMed Web of Science ®Google Scholar
• HwangE, Johnson-ObasekiS, McDonaldJT, ConnellC, CorstenM. Incidence of head and neck cancer and socioeconomic status in Canada from 1992 to 2007. Oral Oncol. 2013;49(11):1072–1076. doi:10.1016/j.oraloncology.2013.08.00224018186
   PubMed Web of Science ®Google Scholar
• OlsenMH, BojeCR, KjaerTK, et al. Socioeconomic position and stage at diagnosis of head and neck cancer - a nationwide study from DAHANCA. Acta Oncol. 2015;54(5):759–766. doi:10.3109/0284186X.2014.99827925734503
   PubMed Web of Science ®Google Scholar
• VartanianJG, CarvalhoAL, ToyotaJ, KowalskiIS, KowalskiLP. Socioeconomic effects of and risk factors for disability in long-term survivors of head and neck cancer. Arch Otolaryngol Head Neck Surg. 2006;132(1):32–35. doi:10.1001/archotol.132.1.3216415426
   PubMedGoogle Scholar
• DemiralAN, SenM, DemiralY, KinayM. The effect of socioeconomic factors on quality of life after treatment in patients with head and neck cancer. Int J Radiat Oncol Biol Phys. 2008;70(1):23–27. doi:10.1016/j.ijrobp.2007.05.05617996388
   PubMed Web of Science ®Google Scholar
• TabernaM, Gil MoncayoF, Jané-SalasE, et al. The Multidisciplinary Team (MDT) approach and quality of care. Front Oncol. 2020;10:85. doi:10.3389/fonc.2020.0008532266126
   PubMed Web of Science ®Google Scholar
• Jager-WittenaarH, DijkstraPU, VissinkA, van der LaanBF, van OortRP, RoodenburgJL. Critical weight loss in head and neck cancer–prevalence and risk factors at diagnosis: an explorative study. Support Care Cancer. 2007;15(9):1045–1050. doi:10.1007/s00520-006-0212-917277925
   PubMed Web of Science ®Google Scholar
• LeesJ. Incidence of weight loss in head and neck cancer patients on commencing radiotherapy treatment at a regional oncology centre. Eur J Cancer Care (Engl). 1999;8(3):133–136. doi:10.1046/j.1365-2354.1999.00156.x10763643
   PubMed Web of Science ®Google Scholar
• SalasS, DevilleJL, GiorgiR, et al. Nutritional factors as predictors of response to radio-chemotherapy and survival in unresectable squamous head and neck carcinoma. Radiother Oncol. 2008;87(2):195–200. doi:10.1016/j.radonc.2008.02.01118342966
   PubMed Web of Science ®Google Scholar
• PaccagnellaA, MorelloM, Da MostoMC, et al. Early nutritional intervention improves treatment tolerance and outcomes in head and neck cancer patients undergoing concurrent chemoradiotherapy. Support Care Cancer. 2010;18(7):837–845. doi:10.1007/s00520-009-0717-019727846
   PubMed Web of Science ®Google Scholar
• FerraoB, NevesPM, SantosT, CapelasML, MakitieA, RavascoP. Body composition changes in patients with head and neck cancer under active treatment: a scoping review. Support Care Cancer. 2020;28(10):4613–4625. doi:10.1007/s00520-020-05487-w32533436
   PubMed Web of Science ®Google Scholar
• McCarterK, BakerAL, BrittonB, et al. Smoking, drinking, and depression: comorbidity in head and neck cancer patients undergoing radiotherapy. Cancer Med. 2018;7(6):2382–2390. doi:10.1002/cam4.149729671955
   PubMed Web of Science ®Google Scholar
• SehlenS, LenkM, HerschbachP, et al. Depressive symptoms during and after radiotherapy for head and neck cancer. Head Neck. 2003;25(12):1004–1018. doi:10.1002/hed.1033614648859
   PubMed Web of Science ®Google Scholar
• ReichM, LicitraL, VermorkenJB, et al. Best practice guidelines in the psychosocial management of HPV-related head and neck cancer: recommendations from the European head and neck cancer society’s make sense campaign. Ann Oncol. 2016;27(10):1848–1854. doi:10.1093/annonc/mdw27227456297
   PubMed Web of Science ®Google Scholar
• Osazuwa-PetersN, SimpsonMC, ZhaoL, et al. Suicide risk among cancer survivors: head and neck versus other cancers. Cancer. 2018;124(20):4072–4079. doi:10.1002/cncr.3167530335190
   PubMed Web of Science ®Google Scholar
• YuGP, MehtaV, BranovanD, HuangQ, SchantzSP. Non-cancer-related deaths from suicide, cardiovascular disease, and pneumonia in patients with oral cavity and oropharyngeal squamous carcinoma. Arch Otolaryngol Head Neck Surg. 2012;138(1):25–32. doi:10.1001/archoto.2011.23622249625
   PubMedGoogle Scholar
• Verdonck-de LeeuwIM, de BreeR, KeizerAL, et al. Computerized prospective screening for high levels of emotional distress in head and neck cancer patients and referral rate to psychosocial care. Oral Oncol. 2009;45(10):e129–e133. doi:10.1016/j.oraloncology.2009.01.01219362038
   PubMed Web of Science ®Google Scholar
• AndersenBL, DeRubeisRJ, BermanBS, et al. Screening, assessment, and care of anxiety and depressive symptoms in adults with cancer: an American society of clinical oncology guideline adaptation. J Clin Oncol. 2014;32(15):1605–1619. doi:10.1200/JCO.2013.52.461124733793
   PubMed Web of Science ®Google Scholar
• KrebberAM, LeemansCR, de BreeR, et al. Stepped care targeting psychological distress in head and neck and lung cancer patients: a randomized clinical trial. BMC Cancer. 2012;12(1):173. doi:10.1186/1471-2407-12-17322574757
   PubMed Web of Science ®Google Scholar
• KrebberAM, JansenF, WitteBI, et al. Stepped care targeting psychological distress in head and neck cancer and lung cancer patients: a randomized, controlled trial. Ann Oncol. 2016;27(9):1754–1760. doi:10.1093/annonc/mdw23027287209
   PubMed Web of Science ®Google Scholar
• VillaA, AkintoyeSO. Dental management of patients who have undergone oral cancer therapy. Dent Clin North Am. 2018;62(1):131–142. doi:10.1016/j.cden.2017.08.01029126490
   PubMedGoogle Scholar
• KellySL, JacksonJE, HickeyBE, SzallasiFG, BondCA. Multidisciplinary clinic care improves adherence to best practice in head and neck cancer. Am J Otolaryngol. 2013;34(1):57–60. doi:10.1016/j.amjoto.2012.08.01023218113
   PubMed Web of Science ®Google Scholar
• StarmerHM, AyoubN, BywardC, et al. The impact of developing a speech and swallow rehab program: improving patient satisfaction and multidisciplinary care. Laryngoscope. 2017;127(11):2578–2581.28561453
   PubMed Web of Science ®Google Scholar
• NuchitS, Lam-UbolA, PaemuangW, et al. Alleviation of dry mouth by saliva substitutes improved swallowing ability and clinical nutritional status of post-radiotherapy head and neck cancer patients: a randomized controlled trial. Support Care Cancer. 2020;28(6):2817–2828. doi:10.1007/s00520-019-05132-131732852
   PubMed Web of Science ®Google Scholar
• LinBM, StarmerHM, GourinCG. The relationship between depressive symptoms, quality of life, and swallowing function in head and neck cancer patients 1 year after definitive therapy. Laryngoscope. 2012;122(7):1518–1525. doi:10.1002/lary.2331222467530
   PubMed Web of Science ®Google Scholar
• LiaoCT, KangCJ, LeeLY, et al. Association between multidisciplinary team care approach and survival rates in patients with oral cavity squamous cell carcinoma. Head Neck. 2016;38(Suppl 1):E1544–E1553. doi:10.1002/hed.2427626890807
   PubMed Web of Science ®Google Scholar
• LightT, RassiEE, MaggioreRJ, et al. Improving outcomes in veterans with oropharyngeal squamous cell carcinoma through implementation of a multidisciplinary clinic. Head Neck. 2017;39(6):1106–1112. doi:10.1002/hed.2472128370667
   PubMed Web of Science ®Google Scholar